187 related articles for article (PubMed ID: 36524089)
1. Zhengyuan capsules for the treatment of chemotherapy-induced cancer-related fatigue in stage IIIB-IV unresectable NSCLC: study protocol for a randomized, multi-center, double-blind, placebo-controlled clinical trial.
Lin J; Yang T; Chen W; Qi X; Cao Y; Zheng X; Chen H; Sun L; Lin L
J Thorac Dis; 2022 Nov; 14(11):4560-4570. PubMed ID: 36524089
[TBL] [Abstract][Full Text] [Related]
2. Zhengyuan capsule for the treatment of cancer-related fatigue in lung cancer patients undergoing operation: a study protocol for a randomized controlled trial.
Zhang ZJ; Zhang M; Wu XT; Cui Q; Guo YJ
J Tradit Chin Med; 2021 Jun; 41(3):486-491. PubMed ID: 34114408
[TBL] [Abstract][Full Text] [Related]
3. Shenmai injection for the treatment of cancer-related fatigue in advanced non-small cell lung cancer patients undergoing chemotherapy: study protocol for a randomized controlled trial.
Zhou Y; Zhao B; Wu W; Yang X; Long S; Deng H; He W; Liao G; Li Q; Xie Z
Trials; 2018 Sep; 19(1):474. PubMed ID: 30180874
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of Jianpishengsui for chemotherapy-related fatigue in patients with non-small cell lung cancer: study protocol for a randomized placebo-controlled clinical trial.
Xiao Z; Hu L; Lin J; Lu L; Huang X; Zhu X; Teo C; Lin L
Trials; 2020 Jan; 21(1):94. PubMed ID: 31948475
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
6. Yifei Sanjie Formula or Placebo With Anlotinib as Second-Line or Above Treatment for Metastatic Non-Small-Cell Lung Cancer: Study Protocol for a Double-Blind, Placebo-Controlled Randomized Pilot Study.
Chen W; Lin J; Yang T; Xin Zhang Z; Tao L; Xiao Z; Chen H; Qi X; Sun L; Cao Y; Lin L
Integr Cancer Ther; 2023; 22():15347354221151147. PubMed ID: 36710490
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of Kyung-Ok-Ko on cancer-related fatigue in lung cancer patients: Study protocol for a randomized, patients-assessor blind, placebo-controlled, parallel-group, single-center trial.
Kim KI; Kong M; Lee SH; Lee BJ
Medicine (Baltimore); 2019 Nov; 98(44):e17717. PubMed ID: 31689808
[TBL] [Abstract][Full Text] [Related]
8. Exploring the Safety, Effectiveness, and Cost-Effectiveness of a Chinese Patent Medicine (Fufang E'jiao Syrup) for Alleviating Cancer-Related Fatigue: A Protocol for a Randomized, Double-Blinded, Placebo-Controlled, Multicenter Trial.
Song Z; Sun LY; Gu SS; Zhu XS; Lai HZ; Lu F; Cui N; Li QY; Wu Y; Xu Y
Integr Cancer Ther; 2021; 20():15347354211002919. PubMed ID: 33834863
[TBL] [Abstract][Full Text] [Related]
9. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.
Brahmer JR; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Zhang J; Lubiniecki GM; Deitz AC; Rangwala R; Reck M
Lancet Oncol; 2017 Dec; 18(12):1600-1609. PubMed ID: 29129441
[TBL] [Abstract][Full Text] [Related]
10. Safety and Efficacy of Mild Moxibustion on Cancer-Related Fatigue in Non-Small-Cell Lung Cancer Patients Undergoing Chemotherapy.
Xu X; Gu F
Comput Math Methods Med; 2022; 2022():6530454. PubMed ID: 35912144
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive TCM treatments combined with chemotherapy for advanced non-small cell lung cancer: A randomized, controlled trial.
Xiao Z; Chen Z; Han R; Lu L; Li Z; Lin J; Hu L; Huang X; Lin L
Medicine (Baltimore); 2021 May; 100(18):e25690. PubMed ID: 33950949
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of an amino acid jelly containing coenzyme Q10 and L-carnitine in controlling fatigue in breast cancer patients receiving chemotherapy: a multi-institutional, randomized, exploratory trial (JORTC-CAM01).
Iwase S; Kawaguchi T; Yotsumoto D; Doi T; Miyara K; Odagiri H; Kitamura K; Ariyoshi K; Miyaji T; Ishiki H; Inoue K; Tsutsumi C; Sagara Y; Yamaguchi T
Support Care Cancer; 2016 Feb; 24(2):637-646. PubMed ID: 26105516
[TBL] [Abstract][Full Text] [Related]
13. The prophylactic and therapeutic effects of moxibustion combined with traditional Chinese medicine decoction for treating chemotherapy-induced myelosuppression in early-stage breast cancer: study protocol for a randomized controlled trial.
Ji Y; Li S; Zhang X; Liu Y; Lu Q; Li Q; Chen W; Sheng J; Jiang K; Liang H; Sha S; Li M; Chen Z; Zheng P; Wang M; Feng Y; Wang L; Wu H; Liu H; Huang Y; Yin Z; Xue X
Trials; 2020 Oct; 21(1):844. PubMed ID: 33046128
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy in conjunction with traditional Chinese medicine for survival of elderly patients with advanced non-small-cell lung cancer: protocol for a randomized double-blind controlled trial.
Zhou ZY; Xu L; Li HG; Tian JH; Jiao LJ; You SF; Han ZF; Jiang Y; Guo HR; Liu H
J Integr Med; 2014 May; 12(3):175-81. PubMed ID: 24861837
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic efficacy of traditional Chinese medicine, Shen-Mai San, in cancer patients undergoing chemotherapy or radiotherapy: study protocol for a randomized, double-blind, placebo-controlled trial.
Lo LC; Chen CY; Chen ST; Chen HC; Lee TC; Chang CS
Trials; 2012 Dec; 13():232. PubMed ID: 23206440
[TBL] [Abstract][Full Text] [Related]
16. The effect of comprehensive rehabilitation program plus chemotherapy on quality of life in patients with postoperative non-small-cell lung cancer: study protocol of a multicenter randomized clinical trial.
Yao J; Jiao L; Yao Y; Lu Y; Shi J; Li J; Chen P; Xu L; Gong Y
Trials; 2020 Apr; 21(1):309. PubMed ID: 32245480
[TBL] [Abstract][Full Text] [Related]
17. Impact of AferBio® on quality of life and chemotherapy toxicity in advanced lung cancer patients (AFERBIO study): protocol study for a phase II randomized controlled trial.
D'Almeida Preto D; Baston MT; Geraige CC; Augusto SB; de Oliveira MA; Mamere AE; Pinto GDJ; Dias JM; De Marchi PRM; Paiva BSR; Paiva CE
BMC Cancer; 2019 Apr; 19(1):382. PubMed ID: 31023257
[TBL] [Abstract][Full Text] [Related]
18. A study protocol for HEalth-Related quality of life-intervention in survivors of Breast and other cancers experiencing cancer-related fatigue using TraditionAL Chinese Medicine: the HERBAL trial.
Yap NY; Loo WS; Zheng HF; Tan QM; Tan TK; Quek LYP; Tan CJ; Toh YL; Ng CC; Ang SK; Tan VKM; Ho HK; Chew L; Loh KW; Tan TJY; Chan A
Trials; 2020 Nov; 21(1):909. PubMed ID: 33187543
[TBL] [Abstract][Full Text] [Related]
19. Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study.
Hui R; Özgüroğlu M; Villegas A; Daniel D; Vicente D; Murakami S; Yokoi T; Chiappori A; Lee KH; de Wit M; Cho BC; Gray JE; Rydén A; Viviers L; Poole L; Zhang Y; Dennis PA; Antonia SJ
Lancet Oncol; 2019 Dec; 20(12):1670-1680. PubMed ID: 31601496
[TBL] [Abstract][Full Text] [Related]
20. Multi-center randomized double-blind controlled clinical study of chemotherapy combined with or without traditional Chinese medicine on quality of life of postoperative non-small cell lung cancer patients.
Xu L; Li H; Xu Z; Wang Z; Liu L; Tian J; Sun J; Zhou L; Yao Y; Jiao L; Su W; Guo H; Chen P; Liu J
BMC Complement Altern Med; 2012 Aug; 12():112. PubMed ID: 22853619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
